Alpha 1-Antitrypsin - Octapharma

Drug Profile

Alpha 1-Antitrypsin - Octapharma

Alternative Names: OctaAlpha1

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency

Most Recent Events

  • 10 Apr 2018 Octapharma withdraws a phase II trial for alpha1-antitrypsin deficiency prior to enrolment as the IND has been closed (NCT03385395)
  • 28 Dec 2017 Octapharma plans a phase II trial for alpha1-antitrypsin deficiency in July 2018 (NCT03385395)
  • 28 Dec 2017 Preclinical trials in Alpha 1-antitrypsin deficiency in Switzerland (IV) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top